PolicyChanges tracks payer policy changes for medical practices and tells you what to do before they take effect.

Create a free accountPolicy Monitoring is free. No card required.
← Back to list
UnitedHealthcareMedicaid · Billing Codes · Medical Benefit Drug Policy · NM · Endocrinology, Rheumatology, Internal Medicine +3 moreHigh impact

Denosumab

Effective date
Jan 1, 2027
Identified
Nov 7, 2026

Summary

Effective 2027-01-01, UnitedHealthcare Community Plan of New Mexico Medicaid expanded its denosumab policy: Jubereq and Osvyrti are preferred products covered under the Diagnosis-Specific Criteria, while Boncresa, Oziltus, and Ponlimsi are non-preferred and covered only when the Preferred Product Criteria and Diagnosis-Specific Criteria are both met. The postmenopausal osteoporosis criteria add a very-high-fracture-risk pathway for initial therapy, and HCPCS codes Q5166, Q5171, and Q5173 were added.

Get alerts when payers change rules like this one

We check UnitedHealthcare and other payers every day and email you when a change matches your specialty and state.

Get UnitedHealthcare alertsPolicy Monitoring is free. No card required.

What to do

Action · 3 steps
01By 2027-01-01: Billing team and providers should confirm which denosumab products the practice dispenses for New Mexico Medicaid members, and update charge entry so Q5166, Q5171, and Q5173 are available for the newly listed biosimilars.
02Before scheduling denosumab for postmenopausal osteoporosis, providers and front desk staff should document the diagnosis-specific criteria, including the very-high-fracture-risk indicators (recent fracture within 12 months, fracture on approved osteoporosis therapy, multiple fractures, fractures on drugs causing skeletal harm, BMD T-score below -3.0, high fall risk, or FRAX thresholds), in the chart so claims for non-preferred products such as Boncresa, Oziltus, or Ponlimsi include supporting documentation.
03Billing team should watch for the payer's next notice on any further product or criteria revisions.

Codes mentioned

Q5166Q5171Q5173

Original notice

Denosumab
uhcprovider.com · Always check the source before changing claims.
View original ↗

Related policy hubs

Summaries are AI-assisted. Always confirm against the original payer notice.

What is PolicyChanges

One workspace for payer rules, prior auth, coding and compliance

Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.

Start freePolicy Monitoring is free. No card required.
Get alerts for changes like thisPolicy Monitoring is free. No card required.Create a free account